PACTR202607921693996进行中（未招募）2 期
A Phase IIb open-label randomized trial to assess the immunogenicity and safety of the malaria vaccine R21/Matrix-M™ combined with post-discharge malaria chemoprevention (PDMC) with dihydroartemisinin-piperaquine (DHA-PPQ) in children 6-60 months of age at high risk for re-admission and death in Ghana.
Kumasi Center for Collaborative Research in Tropical Medicine0 个研究点目标入组 150 人开始时间: 2026年12月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 Month(s) 至 12 Month(s)（—）
- 性别
- All
入选标准
- •for Group A and B: The child will be 6 – 60 months of age at the time of first vaccination, has been admitted to the children`s ward of Saint Francis Xavier Hospital (SFXH) with severe anaemia (haemoglobin level <7.0 g/dL) or with severe P. falciparum malaria (WHO criteria for severe disease)
- •for Group C: healthy children aged 6 – 60 months of age at the time of first vaccination and from the same community irrespective of their hb level.
- •Signed informed consent/thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child to join the trial.
- •The investigator believes that the parents/guardians can and will comply with the requirements of the protocol if the child is enrolled in the study.
- •The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial.
排除标准
- •The child has previously received a malaria vaccine.
- •The child has received an investigational drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine or planned use during the study period.
- •The child is currently participating in another malaria intervention trial or any other clinical intervention trial likely to affect data interpretation of this trial.
- •The child has a history of allergic disease or reactions likely to be exacerbated by any component of the malaria or control vaccine.
- •The child has a history of allergic reactions, significant IgE-mediated events or anaphylaxis to previous immunizations or the study drug DHA-PPQ.
- •The child has a family history of sudden death or of congenital prolongation of the QTc interval, or takes concomitant medication known to prolong QTc interval, or has a prolonged QTc interval >440 ms in the baseline ECG.
- •Pathological biochemistry results (renal and liver function) of more than Grade 1 according to DAIDS Toxicity Scale for the Groups A and B (no biochemistry required for Group C).
- •The child has major congenital defects.
- •The child has severe anaemia associated with clinical signs or symptoms of decompensation, or a haemoglobin of = 5.0 g/dL with indication of blood transfusion.
- •The child has had a blood transfusion or any other blood product within three months of enrolment.
- •The child has been administered immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
- •The child has severe malnutrition requiring hospital admission, taking into consideration weight-for-length/height and/or mid-upper arm circumference, presence of oedema (kwashiorkor) with or without severe wasting.
- •The child has a known severe acute or chronic disease, resulting in clinically significant pulmonary, cardiovascular and gastrointestinal
研究者
相似试验
尚未招募
不适用
A Study of Rusfertide in Japanese Adults With PolycythemiajRCT20312602159
招募中
不适用
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal AdenocarcinomaPancreatic ductal adenocarcinomajRCT2031260004900
尚未招募
不适用
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationGrade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationjRCT203126015910
招募中
1 期
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.2023-510356-23-00Novartis Pharma AG76
招募中
不适用
Study on the ease of swallowing various formulations (tablets and new forms) in patients with post-stroke swallowing difficulties.Dysphagia following strokejRCT104026002616